ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.1721A>C (p.Gln574Pro)

dbSNP: rs1667078647
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001221997 SCV001394076 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2023-06-11 criteria provided, single submitter clinical testing ClinVar contains an entry for this variant (Variation ID: 950312). This variant has not been reported in the literature in individuals affected with MSH2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 574 of the MSH2 protein (p.Gln574Pro). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (PMID: 33357406) indicates that this missense variant is expected to disrupt MSH2 function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV002402680 SCV002713635 likely pathogenic Hereditary cancer-predisposing syndrome 2023-09-05 criteria provided, single submitter clinical testing The p.Q574P variant (also known as c.1721A>C), located in coding exon 11 of the MSH2 gene, results from an A to C substitution at nucleotide position 1721. The glutamine at codon 574 is replaced by proline, an amino acid with similar properties. In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was reported to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 01;108:163-175). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Myriad Genetics, Inc. RCV003449701 SCV004186758 likely pathogenic Lynch syndrome 1 2023-08-03 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 33357406]. This variant is expected to disrupt protein structure [Myriad internal data].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.